• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

johnsonandjohnson

Johnson & Johnson touts drug-releasing lens studies for itchy eyes

March 26, 2019 By Brad Perriello

Johnson & Johnson

Contact lenses imbued with an antihistamine drug reduced itchy eyes in a pair of older studies funded by the vision business at Johnson & Johnson (NYSE:JNJ), the company said today. The Phase 3 studies, conducted in 2007, involved a total of 244 patients, divided into three cohorts. In the first patients wore a plain lens […]

Filed Under: Clinical Trials, Optical/Ophthalmic Tagged With: johnsonandjohnson

FDA approves J&J’s Tremfya self-injection pen for psoriasis

January 30, 2019 By Nancy Crotti

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s  (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Made by J&J subsidiary Janssen Pharmaceuticals (Horsham, Penn.), Tremfya is a biologic therapy that selectively […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Uncategorized Tagged With: AbbVie, FDA, Janssen Pharmaceuticals, johnsonandjohnson

Johnson & Johnson, Apple ink collab for AFib study

January 17, 2019 By Sarah Faulkner

Updated Janssen logo

Johnson & Johnson‘s (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch’s ECG app and irregular rhythm notifications can improve outcomes for people living with atrial fibrillation. The study is slated to measure the impact of the Apple Watch […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Apple, janssen, johnsonandjohnson

How Reggie Groves reinvented Medtronic’s atrial fibrillation biz

December 7, 2018 By Sarah Faulkner

DeviceTalks West

Reva Medical (ASX:RVA) CEO Reggie Groves got her start in the medical device industry at medtech titan Medtronic. In her upcoming keynote interview at DeviceTalks West, Groves will discuss how that experience has shaped her as a leader and an innovator. Here’s a preview: When Reggie Groves joined Medtronic (NYSE:MDT) in 2002, she didn’t know very much about […]

Filed Under: Business/Financial News, Featured, Vascular, Wall Street Beat Tagged With: DeviceTalks West, johnsonandjohnson, Medtronic, Reva Medical, St. Jude

Janssen touts topline data for long-acting, injectable HIV therapy

November 2, 2018 By Sarah Faulkner

Janssen updated logo

Johnson & Johnson‘s (NYSE:JNJ) Janssen touted topline results this week from a Phase III trial of its long-acting, injectable two-drug regimen for the treatment of HIV. The study found that long-acting, once-monthly rilpivirine and cabotegravir had comparable efficacy to GlaxoSmithKline‘s (NYSE:GSK) oral Triumeq product. Janssen and ViiV Healthcare also reported that virologic response and drug resistance […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, janssen, johnsonandjohnson

Carrot raises $25m for tech-enabled smoking cessation program

October 30, 2018 By Sarah Faulkner

Carrot logo

Digital health company Carrot said today that it raised $25 million to commercialize its tech-enabled Pivot smoking cessation program. The round was led by Johnson & Johnson‘s (NYSE:JNJ) strategic venture capital arm, JJDC. New York Life Ventures and existing investors Khosla Ventures, Marc Benioff, founder Dr. David Utley and R7 Partners also contributed to the […]

Filed Under: Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals Tagged With: carrot, johnsonandjohnson

Johnson & Johnson closes $2B LifeScan sale

October 2, 2018 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that closed the $2.1 billion sale of its LifeScan blood glucose monitoring subsidiary to private equity player Platinum Equity. The sale is part of the New Brunswick, N.J.-based healthcare conglomerate’s move to get out of the device end of the diabetes business. Early last year J&J announced a strategic review of the LifeScan, Animas […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: johnsonandjohnson, Platinum Equity

J&J inks collab deal to develop MERS vaccine

September 27, 2018 By Fink Densford

Janssen

Healthcare giant Johnson & Johnson (NYSE:JNJ) today announced a new collaborative deal as it looks to develop a vaccine against Middle East Respiratory Syndrome Coronavirus. The collaborative deal is between J&J’s Janssen Vaccines & Prevention division, the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford, J&J said. Through the deal, Janssen […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

FDA warns of flesh-eating genital infection linked to diabetes drug

August 31, 2018 By Fink Densford

FDA

The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes. The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly & Co., johnsonandjohnson, Merck, Pfizer Inc.

J&J’s Janssen wins FDA nod for first non-chemo treatment for rare blood cancer

August 27, 2018 By Fink Densford

Janssen

Johnson & Johnson‘s (NYSE:JNJ) Janssen division said today that it won new FDA approval for its Imbruvica, clearing it for use in treating the rare blood cancer Waldenström’s macroglobulinemia in combination with ritumixab. The approval expands the label for Imbruvica to include combination use with ritumixab, and represents “the first approved non-chemotherapy combination option for the […]

Filed Under: Food & Drug Administration (FDA), Oncology, Regulatory/Compliance Tagged With: janssen, johnsonandjohnson

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS